Advertisement


Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents

Pan Pacific Lymphoma Conference 2018

Advertisement

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses promising pathways for inhibitors—BTK, PI3K, EZH2, bcl-2—and the clinical trials for single agents and combinations that suggest their potential for lymphoma treatment.



Related Videos

Lymphoma

Laurie H. Sehn, MD, MPH, on HGBCL With Comorbidities: Upfront Therapies

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses the challenges of treating high-grade B-cell lymphoma in older patients and thos...

Lymphoma
Immunotherapy

Stephen M. Ansell, MD, PhD, on Hodgkin Lymphoma: Beyond Checkpoint Inhibitors

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the efficacy of PD-1 blockade in Hodgkin lymphoma, new findings related to PD-1 therapy, current combination approac...

Lymphoma

Andrew D. Zelenetz, MD, PhD, on NHL: Clinical Applications of Genomic Studies

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need...

Issues in Oncology

R. Gregory Bociek, MD, on Ethical Considerations of Cancer Treatment

R. Gregory Bociek, MD, of the University of Nebraska Medical Center, discusses the controversial topic of euthanasia and physician-assisted suicide.

 

Leukemia

Susan M. O’Brien, MD, on CLL: Sequencing Therapy Options

Susan M. O’Brien, MD, of the University of California, Irvine, discusses three oral agents for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma, and the use...

Advertisement

Advertisement



Advertisement